Novartis expands in radio-oncology again with $1.3bn Artios allianceIn its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus Share XNovartis expands in radio-oncology again with $1.3bn Artios alliancehttps://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/
Novartis builds radio-oncology pipeline with iTheranostics dealNovartis has added to its pipeline of radiopharmaceuticals once again, licensing a series of agents from iTheranostics that Share XNovartis builds radio-oncology pipeline with iTheranostics dealhttps://pharmaphorum.com/news/novartis-builds-radio-oncology-pipeline-with-itheranostics-deal/
Novartis says £1.8m Zolgensma is model for gene therapy pricingNovartis has said its gene therapy pricing model, involving a steep one-off payment, could be a template for Share XNovartis says £1.8m Zolgensma is model for gene therapy pricinghttps://pharmaphorum.com/news/novartis-e1-9m-zolgensma-is/
Novartis’ canakinumab falls short in phase 3 lung cancer trialNovartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless Share XNovartis’ canakinumab falls short in phase 3 lung cancer trialhttps://pharmaphorum.com/news/novartis-canakinumab-falls-short-in-phase-3-lung-cancer-trial/
Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ ZolgensmaThe Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment Share XDouble first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensmahttps://pharmaphorum.com/news/double-first-for-scotland-as-it-backs-roches-rozlytrek-novartis-zolgensma/
NICE says NHS should fund Novartis’ £1.79m SMA gene therapyThe NHS should pay for Novartis’ £1.79 million one-off gene therapy for Spinal Muscular Atrophy (SMA) NICE has Share XNICE says NHS should fund Novartis’ £1.79m SMA gene therapyhttps://pharmaphorum.com/news/nice-says-nhs-should-fund-novartis-1-79m-sma-gene-therapy/
Two biotechs target dry eye disease after Novartis’ Xiidra problemsThe pipeline for dry eye disease drugs is beginning to heat up, with two biotechs announcing key developments, Share XTwo biotechs target dry eye disease after Novartis’ Xiidra problemshttps://pharmaphorum.com/news/two-biotechs/
FDA to quickly review Incyte’s Jakafi in chronic GVHDThe FDA is to begin a fast review of Incyte’s Jakafi (ruxolitinib) for patients with chronic graft-versus-host disease Share XFDA to quickly review Incyte’s Jakafi in chronic GVHDhttps://pharmaphorum.com/news/fda-to-quickly-review-incytes-jakafi-in-chronic-gvhd/
No cooling off for pharma digital transformation in 2021COVID-19 has already proved to be a digital accelerant for the pharmaceutical industry, sparking new ideas into life Share XNo cooling off for pharma digital transformation in 2021https://pharmaphorum.com/views-analysis-digital/no-cooling-off-for-pharma-digital-transformation-in-2021/
